An engineered polypeptide comprising: an albumin binding domain polypeptide comprising an amino acid sequence of or having at least 95 % identity to LAX 3 AKX 6 X 7 ANX 10 ELDX 14 YGVSDFYKRLIX 26 KAKTVEGVEALKX 39 X 40 ILX 43 X 44 LP (SEQ ID NO:300); wherein independently of each other: X 3 is selected from E, S, Q and C; X 6 is selected from E, S and C; X 7 is selected from A and S; X 10 is selected from A, S and R; X 14 is selected from A, S, C and K; X 26 is selected from D and E; X 39 is selected from D and E; X 40 is selected from A and E; X 43 is selected from A and K; X 44 is selected from A, S and E; the leucine at position 45 is present or absent; the proline at position 46 is present or absent; with the proviso that the amino acid sequence of the ABD is not LAEAKX a X b AX c X d ELX e KYGVSDX 5 YKX 8 X 9 lX 11 X 12 AX 14 TVEGVX 20 ALX 23 X 24 X 25 ILAALP (SEQ ID NO: 679); wherein independently of each other: X a is selected from V and E; X b is selected from L, E and D; X c is selected from N, L and I; X d is selected from R and K; X e is selected from D and K; X 5 is selected from Y and F; X 8 is selected from N, R and S; X 9 is selected from V, I, L, M, F and Y; X 11 is selected from N, S, E and D; X 12 is selected from R, K and N; X 14 is selected from K and R; X 20 is selected from D, N, Q, E, H, S, R and K; X 23 is selected from K, I and T; X 24 is selected from A, S, T, G, H, L and D; and X 25 is selected from H, E and D; and a first peptide hormone domain, wherein said HD1 is selected from the group consisting of: exendin-4 (SEQ ID NO: 980); exendin-4 (SEQ ID NO: 981); exendin-4 (SEQ ID NO: 680); exendin-4 (SEQ ID NO: 982); exendin-4 (SEQ ID NO: 983); HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:2), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:3), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:4), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:111), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO:112), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO: 113), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:114), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKKKKK (SEQ ID NO:115), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:116), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:117); and HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:118). an albumin binding domain polypeptide comprising an amino acid sequence of or having at least 95 % identity to LAX 3 AKX 6 X 7 ANX 10 ELDX 14 YGVSDFYKRLIX 26 KAKTVEGVEALKX 39 X 40 ILX 43 X 44 LP (SEQ ID NO:300); wherein independently of each other: X 3 is selected from E, S, Q and C; X 6 is selected from E, S and C; X 7 is selected from A and S; X 10 is selected from A, S and R; X 14 is selected from A, S, C and K; X 26 is selected from D and E; X 39 is selected from D and E; X 40 is selected from A and E; X 43 is selected from A and K; X 44 is selected from A, S and E; the leucine at position 45 is present or absent; the proline at position 46 is present or absent; X 3 is selected from E, S, Q and C; X 6 is selected from E, S and C; X 7 is selected from A and S; X 10 is selected from A, S and R; X 14 is selected from A, S, C and K; X 26 is selected from D and E; X 39 is selected from D and E; X 40 is selected from A and E; X 43 is selected from A and K; X 44 is selected from A, S and E; the leucine at position 45 is present or absent; the proline at position 46 is present or absent; X a is selected from V and E; X b is selected from L, E and D; X c is selected from N, L and I; X d is selected from R and K; X e is selected from D and K; X 5 is selected from Y and F; X 8 is selected from N, R and S; X 9 is selected from V, I, L, M, F and Y; X 11 is selected from N, S, E and D; X 12 is selected from R, K and N; X 14 is selected from K and R; X 20 is selected from D, N, Q, E, H, S, R and K; X 23 is selected from K, I and T; X 24 is selected from A, S, T, G, H, L and D; and X 25 is selected from H, E and D; and a first peptide hormone domain, wherein said HD1 is selected from the group consisting of: exendin-4 (SEQ ID NO: 980); exendin-4 (SEQ ID NO: 981); exendin-4 (SEQ ID NO: 680); exendin-4 (SEQ ID NO: 982); exendin-4 (SEQ ID NO: 983); HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:2), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:3), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:4), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:111), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO:112), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO: 113), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:114), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKKKKK (SEQ ID NO:115), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:116), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:117); and HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:118). exendin-4 (SEQ ID NO: 980); exendin-4 (SEQ ID NO: 981); exendin-4 (SEQ ID NO: 680); exendin-4 (SEQ ID NO: 982); exendin-4 (SEQ ID NO: 983); HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:2), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:3), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:4), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:111), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO:112), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPS (SEQ ID NO: 113), HGEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:114), HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKKKKK (SEQ ID NO:115), HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSKEIISKKKKKK (SEQ ID NO:116), HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:117); and HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:118).